

Call for Expression of Interest - Postdoc and PhD positions

The [Aidinis lab](#) located at the [Biomedical Sciences Research Center 'Alexander Fleming'](#) in Athens/Greece is in search of highly motivated researchers to undertake open postdoc and PhD positions. The positions will be related to the Autotaxin (ATX)-Lysophosphatidic acid (LPA) axis in obesity and diabetes and how these affect lung and liver fibrosis, via the modulation of phospholipid and microbiota homeostasis. The Aidinis lab has extensive experience in the ATX/LPA axis [1-4], lung fibrosis [5-7], liver fibrosis [8, 9] and related drug discovery [10, 11] and recently established locally the study of microbiomics [12].

We search for: **1)** a highly motivated **senior postdoc** with background in animal modeling, immunology and molecular and cellular biology, and especially metabolic syndrome-diabetes and/or macrophage homeostasis in health and disease. Additional desired qualifications include technical expertise on lipidomics (HPLC-MS) and/or scRNAseq. He/She must have three-year experience as a postdoc, two first-author publications and excellent command of the English language. The successful candidate will be expected to be independent and able and willing to supervise several PhD/MSc/BSc students and assist in scientific writing. **2)** a **PhD candidate** with experience on basic molecular and cellular methodologies. The candidate should have a master's degree, a diploma (BSc/MSc) study in a relevant field, and excellent command of the English language.

Expressions of interest should be sent electronically to V.Aidinis@Fleming.gr. Candidates should email a cover letter outlining their interests and areas of expertise, together with detailed curriculum vitae, including contact information of two referees.

1. Magkrioti, C., et al., *Autotaxin and chronic inflammatory diseases*. *J Autoimmun*, 2019. **104**: p. 102327.
2. Nikitopoulou, I., et al., *Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis*. *J Exp Med*, 2012. **209**(5): p. 925-33.
3. Magkrioti, C., et al., *The Autotaxin—Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis*. *Cancer Research*, 2018. **78**(13): p. 3634-3644.
4. Fotopoulou, S., et al., *ATX expression and LPA signalling are vital for the development of the nervous system*. *Dev Biol*, 2010. **339**(2): p. 451-64.
5. Oikonomou, N., et al., *Pulmonary Autotaxin Expression Contributes to the Pathogenesis of Pulmonary Fibrosis*. *Am J Respir Cell Mol Biol*, 2012.
6. Ninou, I., C. Magkrioti, and V. Aidinis, *Autotaxin in Pathophysiology and Pulmonary Fibrosis*. *Front Med*, 2018. **5**: p. 180.
7. Ntatsoulis, K., et al., *Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target*. *Front Immunol*, 2021. **12**: p. 687397.
8. Kaffe, E., et al., *Hepatocyte autotaxin expression promotes liver fibrosis and cancer*. *Hepatology*, 2017. **65**(4): p. 1369-1383.
9. Kaffe, E., C. Magkrioti, and V. Aidinis, *Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer*. *Cancers (Basel)*, 2019. **11**(11).
10. Matralis, A.N., A. Afantitis, and V. Aidinis, *Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials*. *Med Res Rev*, 2019. **39**(3): p. 976-1013.
11. Magkrioti, C., et al., *Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors*. *Int J Mol Sci*, 2020. **21**(19).
12. Galaris, A., et al., *Obesity Reshapes the Microbial Population Structure along the Gut-Liver-Lung Axis in Mice*. *Biomedicines*, 2022. **10**(2).